FindTrial
Sign In

A comparative study of 0.375% Ropivacaine versus 0.25% Bupivacaine for post operative pain relief following upper abdominal surgeries using ultrasound guided transversus abdominis plane block

A comparative evaluation of post operative analgesia using 0.375% Ropivacaine and 0.25% Bupivacaine following ultrasound guided transversus abdominis plane block in adult patients undergoing elective upper abdominal surgeries under general anaesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052181
Enrollment
50
Registered
2023-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Ropivacaine: Dose is 2.5mg/kg 15ml of local anesthetic injected in TAP Plane bilaterally Duration of intervention: Not applicable Control Intervention1: Bupivacaine: Dose is 2mg/kg 15ml

Sponsors

Department of anesthesia ABVIMS AND DR RML HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult patients in the age group 18 to 60 years (BMI 18-30kg/m2) 2. Undergoing elective upper abdominal surgery under standard general anaesthesia. 3. ASA Grade I and II patients.

Exclusion criteria

Exclusion criteria: Pregnant Women Allergy to opioids, amide group of local anaesthetics and non-steroidal antiinflammatory drugs Coagulopathy or bleeding disorder. Infection at block site. Patients with cardiovascular, pulmonary or neurological diseases.

Design outcomes

Primary

MeasureTime frame
Assessment of post operative pain using VASTimepoint: Thirty minutes Second hour Fourth hour Eighth hour Twelfth hour Twenty fourth hour—

Secondary

MeasureTime frame
Duration of post operative analgesiaTimepoint: time between institution of block and requirement of first rescue analgesia;Post operative nausea, vomiting or any other adverse effectTimepoint: Thirty minutes Second hour Fourth hour Eighth hour Twelfth hour Twenty fourth hour—

Countries

India

Contacts

Public ContactUMA HARIHARAN

ABVIMS AND DR. RML HOSPITAL

uma1708@gmail.com9811271093

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026